Qiagen (QGEN) EBT Margin (2009 - 2025)

Qiagen (QGEN) posted EBT Margin of 20.2% for Q4 2025, down 20.14% sequentially from 25.3% in Q3 2025, and up 702.0% YoY from 2.52% in Q4 2024.

Qiagen (QGEN) EBT Margin (2009 - 2025) Analysis & Trends

Qiagen has reported EBT Margin for 17 years, with the latest figure at 20.2% in Q4 2025.

Quarterly EBT Margin rose 702.0% year-over-year to 20.2% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 23.46% (up 1844.0% YoY) and the FY2025 annual result came in at 23.46%, up 1733.0% from the prior year.
EBT Margin declined to 20.2% in Q4 2025 per QGEN's latest filing, from 25.3% in the prior quarter.
Over five years, EBT Margin peaked at 31.11% in Q1 2022 and troughed at 45.02% in Q2 2024.
A 5-year average of 18.84% and a median of 22.41% in 2022 frame the typical range for EBT Margin.
The sharpest annual moves came in 2024 and 2025: EBT Margin sank 6569 bps in 2024, then surged 6879 bps in 2025.
Over 5 years, EBT Margin stood at 14.57% in 2021, then soared by 46 bps to 21.25% in 2022, then climbed by 10 bps to 23.35% in 2023, then tumbled by 44 bps to 13.18% in 2024, then soared by 53 bps to 20.2% in 2025.
According to Business Quant data, EBT Margin over the past three periods registered 20.2%, 25.3%, and 23.77% for Q4 2025, Q3 2025, and Q2 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Thermo Fisher Scientific	234.15 Bn	230.09 Bn	8.34 Bn	16.04%
2	Danaher	152.10 Bn	147.75 Bn	3.61 Bn	17.21%
3	Natera	48.48 Bn	47.38 Bn	486.15 Mn	-8.93%
4	Agilent Technologies	44.35 Bn	42.55 Bn	990.00 Mn	22.23%
5	Iqvia Holdings	43.68 Bn	41.60 Bn	1.44 Bn	6.89%
6	Idexx Laboratories	43.02 Bn	42.83 Bn	779.09 Mn	34.29%
7	Illumina	34.39 Bn	33.22 Bn	770.00 Mn	22.43%
8	Mettler Toledo International	28.29 Bn	28.24 Bn	650.22 Mn	28.17%
9	Labcorp Holdings	27.51 Bn	27.37 Bn	1.11 Bn	10.36%
10	Qiagen	9.49 Bn	8.72 Bn	-	-

Download Data